Biofrontera Wins Patent Challenge; Key Sun Pharma Patent Claims Ruled Unpatentable

summarizeSummary

Biofrontera Inc. announced a significant legal victory as the U.S. Patent Trial and Appeal Board found all challenged claims of one of Sun Pharma's patents, central to an ongoing infringement lawsuit, to be unpatentable.

check_boxKey Events

• Patent Claims Ruled Unpatentable

  The U.S. Patent Trial and Appeal Board issued a Final Written Decision on February 23, 2026, finding all challenged claims of Sun Pharma's U.S. Patent No. 11,697,028 to be unpatentable.

• Strengthens Legal Defense

  This decision is a significant victory for Biofrontera in its ongoing patent infringement lawsuit with Sun Pharma, weakening the competitor's claims related to the '028 patent.

• Impact on Other Proceedings Undetermined

  The ruling's full impact on the pending U.S. District Court and International Trade Commission proceedings is not yet determinable, and Sun Pharma retains rights to appeal the decision. The decision does not affect a separate patent ('512) that was denied review on administrative grounds.

auto_awesomeAnalysis

This 8-K reports a material positive development in Biofrontera's ongoing patent infringement dispute with Sun Pharmaceutical Industries. The U.S. Patent Trial and Appeal Board's decision to invalidate all challenged claims of Sun Pharma's '028 patent significantly strengthens Biofrontera's defense against the infringement allegations. While the full impact on the pending district court and International Trade Commission proceedings is yet to be determined, this ruling removes a key piece of intellectual property from Sun Pharma's case. This legal win, following recent positive clinical trial results and strong preliminary revenues, provides a boost to investor sentiment, especially as the company navigates a Nasdaq minimum bid price deficiency.